Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
- Resource Type
- Article
- Authors
- Kopmar, Noam E.; Gooley, Ted; Curley, Niall; Russell, Kathryn; Shaw, Carole; Schonhoff, Kelda; Lim, John; Halpern, Anna B.; Walter, Roland B.; Scott, Bart L.; Appelbaum, Jacob; Hendrie, Paul C.; Estey, Elihu H.; Percival, Mary-Elizabeth M.
- Source
- Leukemia & Lymphoma. May2023, Vol. 64 Issue 5, p1057-1059. 3p.
- Subject
- *CYTARABINE
*MITOXANTRONE
*GRANULOCYTE-colony stimulating factor
*TUMORS
*BLAST injuries
- Language
- ISSN
- 1042-8194
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. SWOG S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7 + 3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA + V) in younger patients with previously untreated acute myeloid leukemia (AML). Outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and other high-grade myeloid neoplasms remain poor, prompting the need for improved salvage therapies. [Extracted from the article]